The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
1. AbsTrACT Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory Clostridium difficile
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 7×
“One patient with a history of autonomic dysfunction experienced dizziness with diarrhoea after FMT [15].”
BackgroundInfluentialThe well-built clinical question: A key to evidence-based decisions
(1995) · ACP Journal Club · doi:10.7326/acpjc-1995-123-3-a12 · Cited by 2,931
Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
The gut microbiota and host health: a new clinical frontier
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A., Hirschfield, G. M., Hold, G., Quraishi, M. N., Kinross, J., Smidt, H., Tuohy, K. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309990 · Cited by 2,302
Self-citationGut microbiota and IBD: causation or correlation?
Ni, J., Wu, G. D., Albenberg, L., & Tomov, V. T. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.88 · Cited by 1,778
Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499
Proton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371 · cited 1×
“The rationale for the use of proton pump inhibitors (PPI) prior to upper GI FMT is to minimise acidity which may impair engraftment of transplanted microorganisms; however, PPIs have been shown to alter the gut microbiota [122,123], and have also been associated with primary and recurrent CDI [124,125].”
BackgroundParamsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., Leong, R. W. L., Connor, S., Ng, W., Paramsothy, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30182-4 · Cited by 1,276
European consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207 · cited 3×
“Warm water baths have been recommended to speed thawing [6]; however, the working group thought that this should be strongly discouraged, as this may introduce risks of cross contamination by Pseudomonas species (and other contaminants) from the water bath [111,112], and may reduce bacterial viability in the FMT.”
BackgroundMethodKootte, R. S., Levin, E., Salojärvi, J., Smits, L. P., Hartstra, A. V., Udayappan, S. D., Hermes, G., Bouter, K. E., Koopen, A. M., Holst, J. J., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.008 · Cited by 1,039
Treating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003
Rossen, N. G., Fuentes, S., van der Spek, M. J., Tijssen, J. G., Hartman, J. H. A., Duflou, A., Löwenberg, M., van den Brink, G. R., Mathus-Vliegen, E. M. H., de Vos, W. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.045 · Cited by 921 · cited 4×
“Most of the serious adverse events were a consequence of worsening colitis: one patient who received FMT required a colectomy [140].”
BackgroundMethodInfluentialKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Antibiotic-Induced Changes in the Intestinal Microbiota and Disease
Becattini, S., Taur, Y., & Pamer, E. G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.04.003 · Cited by 901
Petrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault, M. C., Brown, E. M., Schroeter, K., & Allen-Vercoe, E. (2013) · Microbiome · doi:10.1186/2049-2618-1-3 · Cited by 731
Ott, S. J., Waetzig, G. H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J. A., Cassidy, L., Tholey, A., Fickenscher, H., Seegert, D., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.010 · Cited by 695 · cited 1×
“Previous research has demonstrated that commensal bacteria cultured from the stool of healthy donors [22], sterile faecal filtrate [23], and/or spores of Firmicutes derived from ethanol-treated stool from healthy donors [24] may have similar efficacy to conventional FMT in treating CDI, although results of the latter…”
ResultBrandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672 · cited 5×
“The majority of studies specified either 24 hours [15,42,44,45,50,59,131] or 48 hours [46,47,54,65], however some allowed a range from 1-3 days [16,49,57,58,60].”
BackgroundInfluentialKelly, C. R., Ihunnah, C., Fischer, M., Khoruts, A., Surawicz, C., Afzali, A., Aroniadis, O., Barto, A., Borody, T., Giovanelli, A., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.133 · Cited by 636
Youngster, I., Russell, G. H., Pindar, C., Ziv-Baran, T., Sauk, J., & Hohmann, E. L. (2014) · JAMA · doi:10.1001/jama.2014.13875 · Cited by 629
Lee, C. H., Steiner, T., Petrof, E. O., Smieja, M., Roscoe, D., Nematallah, A., Weese, J. S., Collins, S., Moayyedi, P., Crowther, M., et al. (2016) · JAMA · doi:10.1001/jama.2015.18098 · Cited by 627 · cited 9×
“Minor subsequent adverse events have included a range of GI side effects including self-limiting abdominal discomfort [14,17,62,80], nausea [14,54,75], flatulence [14,16,17,46,47, 54,62], self-limiting irregular bowel movements [46], C.”
BackgroundInfluentialQuraishi, M. N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., & Iqbal, T. H. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14201 · Cited by 617
Kao, D., Roach, B., Silva, M., Beck, P., Rioux, K., Kaplan, G. G., Chang, H.-J., Coward, S., Goodman, K. J., Xu, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.17077 · Cited by 615
Effects of antibiotics on gut microbiota
Lange, K., Buerger, M., Stallmach, A., & Bruns, T. (2016) · Digestive Diseases · doi:10.1159/000443360 · Cited by 607
Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., & Hohmann, E. L. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu135 · Cited by 467 · cited 9×
“Minor subsequent adverse events have included a range of GI side effects including self-limiting abdominal discomfort [14,17,62,80], nausea [14,54,75], flatulence [14,16,17,46,47, 54,62], self-limiting irregular bowel movements [46], C.”
BackgroundInfluentialJohnsen, P. H., Hilpüsch, F., Cavanagh, J. P., Leikanger, I. S., Kolstad, C., Valle, P. C., & Goll, R. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30338-2 · Cited by 437
Cammarota, G., Ianiro, G., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000046 · Cited by 428
Weight Gain After Fecal Microbiota Transplantation
Alang, N., & Kelly, C. R. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv004 · Cited by 403
Mattila, E., Uusitalo–Seppälä, R., Wuorela, M., Lehtola, L., Nurmi, H., Ristikankare, M., Moilanen, V., Salminen, K., Seppälä, M., Mattila, P. S., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.037 · Cited by 371 · cited 4×
“Regimens have included vancomycin alone [12,14,18,40,44,60,64,90,121], metronidazole or vancomycin [45,46,86,126], or alternatively vancomycin, fidaxomicin or metronidazole [61], with one study using a range of regimens which included rifaximin [127].”
BackgroundMethodInfluentialMcDonald, E. G., Milligan, J., Frenette, C., & Lee, T. C. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.42 · Cited by 216
Orenstein, R., Dubberke, E., Hardi, R., Ray, A., Mullane, K., Pardi, D. S., & Ramesh, M. S. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ938 · Cited by 197
Agrawal, M., Aroniadis, O. C., Brandt, L. J., Kelly, C., Freeman, S., Surawicz, C., Broussard, E., Stollman, N., Giovanelli, A., Smith, B., et al. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000410 · Cited by 186 · cited 5×
“difficile-toxin negative diarrhoea [57,60], constipation [14,15,47,60,75] and constitutional symptoms/temperature disturbance [14,17].”
BackgroundInfluentialFischer, M., Sipe, B. W., Rogers, N. A., Cook, G. K., Robb, B. W., Vuppalanchi, R., & Rex, D. K. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13290 · Cited by 168
Varier, R. U., Biltaji, E., Smith, K. J., Roberts, M. S., Kyle Jensen, M., LaFleur, J., & Nelson, R. E. (2015) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2014.80 · Cited by 68
Cited by
Gut microbial metabolites as multi-kingdom intermediates
Krautkramer, K. A., Fan, J., & Bäckhed, F. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0438-4 · Cited by 1,398
Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
Guo, X. Y., Liu, X. J., & Hao, J. Y. (2020) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12849 · Cited by 336
Baunwall, S. M. D., Lee, M. M., Eriksen, M. K., Mullish, B. H., Marchesi, J. R., Dahlerup, J. F., & Hvas, C. L. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100642 · Cited by 300
Self-citationPeery, A. F., Kelly, C. R., Kao, D., Vaughn, B. P., Lebwohl, B., Singh, S., Imdad, A., & Altayar, O. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.008 · Cited by 258
Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology
Khoruts, A., Staley, C., & Sadowsky, M. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0350-4 · Cited by 155
Metadata
- Authors
- Mullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D., Colville, A., Bhala, N., Iqbal, T. H., Settle, C., Kontkowski, G., Hart, A. L., Hawkey, P. M., Williams, H. R., & Goldenberg, S. D.
- Venue
- Journal of Hospital Infection
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 100
- Pages
- S1-S31
- ISSN
- 0195-6701 (ISSN-L)
- OpenAlex
- W4242502405
- Cited by
- 79
- References
- 35
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.